Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859165 | 0.80 | LPAR3 (0.44) | LPAR3LPAR2LPAR1ENPP2MPI | |
| SCHEMBL18501086 | 0.77 | LPAR3 (0.43) | LPAR3LPAR2LPAR1ENPP2SAT1 | |
| SCHEMBL4098549 | 0.77 | SAT1 (0.53) | LPAR3LPAR2LPAR1ENPP2SAT1 | |
| SCHEMBL13401021 | 0.75 | LPAR3 (0.42) | LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL6528738 | 0.75 | LPAR3 (0.52) | ANPEPLPAR3LPAR2LPAR1MMP1 | |
| SCHEMBL12873247 | 0.74 | ANPEP (0.57) | ANPEPMMP1MMP8 | |
| SCHEMBL9546919 | 0.73 | — | — | |
| SCHEMBL3429682 | 0.72 | LPAR3 (0.39) | LPAR3LPAR2LPAR1ENPP2MPI | |
| SCHEMBL3429685 | 0.72 | LPAR3 (0.39) | LPAR3LPAR2LPAR1ENPP2SAT1 | |
| SCHEMBL13400489 | 0.72 | LPAR3 (0.59) | LPAR3LPAR2LPAR1ENPP2SAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |